Agomab Announces Pricing of Initial Public Offering

Rhea-AI Summary

Agomab (Nasdaq: AGMB) priced its initial public offering of 12,500,000 ADSs at $16.00 per ADS, implying gross proceeds of approximately $200.0 million before fees. The ADSs are expected to begin trading on February 6, 2026 and the offering is expected to close on February 9, 2026.

The company granted underwriters a 30‑day option to purchase an additional 1,875,000 ADSs. Joint book‑running managers include J.P. Morgan, Morgan Stanley, Leerink Partners and Van Lanschot Kempen.

Positive

• Gross proceeds of $200.0 million before underwriting discounts
• Expected Nasdaq listing on February 6, 2026 under ticker AGMB
• Underwriters granted a 30‑day option for an additional 1,875,000 ADSs

Negative

• Offering represents primary issuance of 12,500,000 ADSs, diluting existing equity
• Net proceeds will be reduced by underwriting discounts, commissions and offering expenses

ANTWERP, Belgium, February 5, 2026 (GLOBE NEWSWIRE) – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab”), a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need, today announced the pricing of its initial public offering of 12,500,000 American Depositary Shares (“ADSs”) representing 12,500,000 of its common shares, at a public offering price of $16.00 per ADS. The gross proceeds to Agomab from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be $200.0 million. All of the ADSs are being offered by Agomab. In addition, Agomab has granted the underwriters a 30-day option to buy an additional 1,875,000 ADSs at the initial public offering price, less underwriting discounts and commissions.

The ADSs are expected to begin trading on the Nasdaq Global Select Market on February 6, 2026, under the ticker symbol “AGMB”. The offering is expected to close on February 9, 2026, subject to the satisfaction of customary closing conditions.

J.P. Morgan, Morgan Stanley, Leerink Partners and Van Lanschot Kempen are acting as joint book-running managers for the offering.

A registration statement relating to this offering has been filed with the Securities and Exchange Commission and was declared effective on January 30, 2026. The offering is being made only by means of a prospectus. Copies of the final prospectus, when available, may be obtained from:
J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com; Morgan Stanley & Co. LLC, Attn: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, or by email at prospectus@morganstanley.com; Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, Massachusetts 02109, by telephone at (800) 808-7525, ext. 6105, or by email at syndicate@leerink.com; and Van Lanschot Kempen (USA) Inc., 880 Third Avenue, 17th floor, New York, New York 10022, or by email at usa@vanlanschotkempen.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

No public offering will be made and no one has taken any action that would, or is intended to, permit a public offering in any country or jurisdiction, other than the United States, where any such action is required, including in Belgium. The transaction to which this press release relates will only be available to, and will be engaged in only with, in member states of the European Economic Area (including Belgium), persons falling within the meaning of Article 2(e) of Regulation (EU) 2017/1129 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and in the United Kingdom, investment professionals falling within article 19 (5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”), persons falling within article 49 (2), (a) to (d) of the Order and other persons to whom it may lawfully be communicated.

About Agomab
Agomab is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Agomab’s product candidates are designed to target established pathways and utilize validated modalities with the aim of increasing efficacy while avoiding systemic toxicities in order to overcome the limitations of prior therapeutic approaches. Agomab’s mission is to develop disease-modifying therapeutics that aim to resolve fibrosis and restore organ function to enable patients with these disorders to live fuller and healthier lives.

Cautionary Note Regarding Forward-Looking Statements
This press release includes certain disclosures that contain “forward-looking statements,” including, without limitation, statements regarding Agomab’s expectations regarding the commencement of trading of its ADSs on the Nasdaq Global Select Market, the completion and timing of the closing of the offering and the anticipated gross proceeds from the offering. Forward-looking statements are based on Agomab’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to the satisfaction of customary closing conditions and the completion of the offering, and the risks inherent in biopharmaceutical product development. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” section of the registration statement filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Agomab undertakes no duty to update such information except as required under applicable law. Readers should not rely upon the information on this page as current or accurate after its publication date.

Contacts

Investors
Sofie Van Gijsel
VP of Investor Relations
E-Mail: sofie.vangijsel@agomab.com
Phone: +1 781 296 1143

Media
Stephanie May or Joe Rayne
Trophic Communications
E-Mail: agomab@trophic.eu
Phone: +49 171 1855682

FAQ

What price did Agomab (AGMB) set for its IPO and how many ADSs were offered?

Agomab set the IPO price at $16.00 per ADS for 12,500,000 ADSs. According to the company, all ADSs are being offered by Agomab, producing approximately $200.0 million in gross proceeds before fees.

When will Agomab ADSs (AGMB) begin trading on Nasdaq and what is the ticker?

Agomab ADSs are expected to begin trading on Nasdaq on February 6, 2026 under the ticker AGMB. According to the company, the offering is slated to close on February 9, 2026, subject to customary conditions.

How much gross capital will Agomab (AGMB) raise from the IPO and what reduces that amount?

The IPO is expected to raise about $200.0 million in gross proceeds before fees. According to the company, underwriting discounts, commissions and offering expenses will reduce the net proceeds to the issuer.

Does Agomab (AGMB) include an overallotment option for more ADSs and how large is it?

Yes. Agomab granted the underwriters a 30‑day option to buy up to 1,875,000 additional ADSs. According to the company, this overallotment can increase the size of the offering if exercised.

Who are the lead underwriters for Agomab's (AGMB) IPO and how can investors obtain the prospectus?

Joint book‑running managers are J.P. Morgan, Morgan Stanley, Leerink Partners, and Van Lanschot Kempen. According to the company, final prospectus copies will be available from those underwriters upon request.

Will the Agomab (AGMB) offering be available outside the United States?

The offering will not be a public offering outside the United States in jurisdictions where not permitted. According to the company, sales outside the U.S. are limited to specific qualified investors under local rules.